# US 2015/0175685 A1 · HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0175685 A1
- Document ID: US20150175685A1
- Status: Published application
- Kind: A1
- Application number: 14/575,067
- Filed: 2014-12-18
- Published: 2015-06-25
- Earliest claimed: 2013-12-20
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Fiona Grueninger; Guy Georges; Olaf Mundigl; Michael Schraeml; Bernd Bohrmann; Ulrich Goepfert; Joerg Benz; Hubert Kettenberger
- Web page: https://patentgrep.com/patent/US20150175685A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody
i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO: 03, and/or
ii) does not bind to full length human Tau (SEQ ID NO: 01) at 1 μg/mL, and/or
iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), and/or
iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), and/or
v) specifically binds to human Tau that has the amino acid sequence of SEQ ID NO: 01 and that has the amino acid mutation S422A.

### Claim 22

A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody comprises
a) in the heavy chain variable domain the HVRs of SEQ ID NO: 08, 18 and 10, or
b) in the heavy chain variable domain the HVRs of SEQ ID NO: 08, 09 and 10.

### Claim 23 (depends on 22)

The humanized antibody according to claim 22, further comprising
a) in the light chain variable domain the HVRs of SEQ ID NO: 13, 14 and 15, or
b) in the light chain variable domain the HVRs of SEQ ID NO: 12, 05 and 15.

### Claim 24 (depends on 22)

The humanized antibody according to claim 22, comprising
a) in the heavy chain variable domain the HVRs of SEQ ID NO: 08, 18 and 10, and in the light chain variable domain the HVRs of SEQ ID NO: 13, 14 and 15, or
b) in the heavy chain variable domain the HVRs of SEQ ID NO: 08, 09 and 10, and in the light chain variable domain the HVRs of SEQ ID NO: 12, 05 and 15, or
c) in the heavy chain variable domain the HVRs of SEQ ID NO: 08, 09 and 10, and in the light chain variable domain the HVRs of SEQ ID NO: 13, 14 and 15.

### Claim 25 (depends on 22)

The humanized antibody according to claim 22, comprising
a) a heavy chain variable domain of SEQ ID NO: 20 and a light chain variable domain of SEQ ID NO: 17, or
b) a heavy chain variable domain of SEQ ID NO: 19 and a light chain variable domain of SEQ ID NO: 16, or
c) a heavy chain variable domain of SEQ ID NO: 19 and a light chain variable domain of SEQ ID NO: 17, or
d) a heavy chain variable domain of SEQ ID NO: 21 and a light chain variable domain of SEQ ID NO: 17.

### Claim 26 (depends on 22)

The humanized antibody according to claim 22, wherein the antibody is effector function silent.

### Claim 27 (depends on 23)

The humanized antibody according to claim 23, wherein the antibody is effector function silent.

### Claim 28 (depends on 22)

The humanized antibody according to claim 22, wherein the antibody
i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO: 03, and/or
ii) does not bind to full length human Tau (SEQ ID NO: 01) at 1 μg/mL, and/or
iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), and/or
iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02).

### Claim 29 (depends on 23)

The humanized antibody according to claim 23, wherein the antibody
i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO: 03, and/or
ii) does not bind to full length human Tau (SEQ ID NO: 01) at 1 μg/mL, and/or
iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), and/or
iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02).

### Claim 30 (depends on 22)

The humanized antibody according to claim 22, wherein the antibody has an EC50 value for
a) the human Tau(pS422) fragment that has the amino acid sequence of SEQ ID NO: 03 of 6 ng/mL or less, and/or
b) the full length human Tau(pS422) that has the amino acid sequence of SEQ ID NO: 02 of 4.5 ng/mL or less, and/or
c) aggregates of human Tau (pS422) that has the amino acid sequence of SEQ ID NO: 02 of 30 ng/mL or less, and/or
d) the human Tau that has the amino acid sequence of SEQ ID NO: 01 and that has the amino acid mutation S422A of 125 ng/mL or less.

### Claim 31 (depends on 23)

The humanized antibody according to claim 23, wherein the antibody has an EC50 value for
a) the human Tau(pS422) fragment that has the amino acid sequence of SEQ ID NO: 03 of 6 ng/mL or less, and/or
b) the full length human Tau(pS422) that has the amino acid sequence of SEQ ID NO: 02 of 4.5 ng/mL or less, and/or
c) aggregates of human Tau (pS422) that has the amino acid sequence of SEQ ID NO: 02 of 30 ng/mL or less, and/or
d) the human Tau that has the amino acid sequence of SEQ ID NO: 01 and that has the amino acid mutation S422A of 125 ng/mL or less.

### Claim 32 (depends on 22)

The humanized antibody according to claim 22, wherein the antibody specifically binds to human Tau(pS422) (SEQ ID NO: 02) and does not bind to human Tau (SEQ ID NO: 01).

### Claim 33 (depends on 23)

The humanized antibody according to claim 23, wherein the antibody specifically binds to human Tau(pS422) (SEQ ID NO: 02) and does not bind to human Tau (SEQ ID NO: 01).

### Claim 34 (depends on 24)

The humanized antibody according to claim 24, wherein the antibody specifically binds to human Tau(pS422) (SEQ ID NO: 02) and does not bind to human Tau (SEQ ID NO: 01).

### Claim 35 (depends on 22)

The humanized antibody according to claim 22, wherein the antibody is
a) a full length antibody of the human subclass IgG1, or
b) a full length antibody of the human subclass IgG4, or
c) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G,
d) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G,
e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain, or
f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

### Claim 36 (depends on 23)

The humanized antibody according to claim 23, wherein the antibody is
a) a full length antibody of the human subclass IgG1, or
b) a full length antibody of the human subclass IgG4, or
c) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G,
d) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G,
e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain, or
f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P3290 in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

### Claim 37 (depends on 24)

The humanized antibody according to claim 24, wherein the antibody is
a) a full length antibody of the human subclass IgG1, or
b) a full length antibody of the human subclass IgG4, or
c) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G,
d) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G,
e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain, or
f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

### Claim 38 (depends on 30)

The humanized antibody according to claim 30, wherein the antibody is
a) a full length antibody of the human subclass IgG1, or
b) a full length antibody of the human subclass IgG4, or
c) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G,
d) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G,
e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain, or
f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

### Claim 39 (depends on 32)

The humanized antibody according to claim 32, wherein the antibody is
a) a full length antibody of the human subclass IgG1, or
b) a full length antibody of the human subclass IgG4, or
c) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G,
d) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G,
e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain, or
f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

### Claim 40 (depends on 21)

A pharmaceutical formulation comprising the humanized antibody according to claim 21 and a pharmaceutically acceptable carrier.

### Claim 41 (depends on 40)

The pharmaceutical formulation according to claim 40, further comprising an anti-human alpha-synuclein antibody or an anti-Abeta antibody.

### Claim 42 (depends on 21)

A method for treating Alzheimer's disease, said method comprising administering to a patient in need thereof, a pharmaceutically effective amount of the humanized anti-body of claim 21, and wherein the Alzheimer's disease is prodromal Alzheimer's disease, or mild Alzheimer's disease.

### Claim 43 (depends on 21)

A method for reducing Tau(pS422) induced neurodegeneration, said method comprising administering the humanized antibody of claim 21 to a patient in need of thereof.

### Claim 44 (depends on 42)

The method according to claim 42, wherein the humanized antibody is for maintaining cognition and function.

### Claim 45 (depends on 21)

A method for slowing the rate of cognitive and functional decline, said method comprising administering to patient in need thereof the humanized antibody of claim 21.

### Claim 46 (depends on 21)

A method for treating prodromal Alzheimer's disease, or mild Alzheimer's disease, said method comprising administering to a patient in need thereof, a pharmaceutically effective amount of humanized antibody of claim 21 and wherein Tau(pS422) induced neurodegeneration is reduced.

### Claim 47 (depends on 22)

A pharmaceutical formulation comprising the humanized antibody according to claim 22 and a pharmaceutically acceptable carrier.

### Claim 48 (depends on 48)

The pharmaceutical formulation according to claim 48, further comprising an anti-human alpha-synuclein antibody or an anti-Abeta antibody.

### Claim 49 (depends on 22)

A method for treating Alzheimer's disease, said method comprising administering to a patient in need thereof, a pharmaceutically effective amount of the humanized anti-body of claim 22, and wherein the Alzheimer's disease is prodromal Alzheimer's disease, or mild Alzheimer's disease.

### Claim 50 (depends on 22)

A method for reducing Tau(pS422) induced neurodegeneration, said method comprising administering the humanized antibody of claim 22 to a patient in need of thereof.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the humanized antibody is for maintaining cognition and function.

### Claim 52 (depends on 51)

The method according to claim 51, wherein the humanized antibody is for maintaining cognition and function.

### Claim 53 (depends on 22)

A method for slowing the rate of cognitive and functional decline, said method comprising administering to patient in need thereof the humanized antibody of claim 22.

### Claim 54 (depends on 22)

A method for treating prodromal Alzheimer's disease, or mild Alzheimer's disease, said method comprising administering to a patient in need thereof, a pharmaceutically effective amount of humanized antibody of claim 22 and wherein Tau(pS422) induced neurodegeneration is reduced.

### Claim 55

A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody
i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO: 03, and
ii) does not bind to full length human Tau (SEQ ID NO: 01) at 1 μg/mL, and
iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), and
iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), and
v) specifically binds to human Tau that has the amino acid sequence of SEQ ID NO: 01 and that has the amino acid mutation S422A.

### Claim 56

A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody
i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO: 03, or
ii) does not bind to full length human Tau (SEQ ID NO: 01) at 1 μg/mL, or
iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), or
iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), or
v) specifically binds to human Tau that has the amino acid sequence of SEQ ID NO: 01 and that has the amino acid mutation S422A.
